Keywords: prohance, launch, bristol-myers, squibb, launched, its, gadoteridol
PROHANCE LAUNCH
Article | 22 February 1993
- Bristol-Myers Squibb has launched its ProHance (gadoteridol) non-ionic magnetic resonance imaging agent in the UK. The agent is indicated for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
